EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Scientific approaches to defining HPV vaccine‐induced protective immunity

Matti Lehtinen iD, Pierre van Damme, Simon Beddows, Ligia A Pinto, Filipe Mariz, Penelope Gray iD, Joakim Dillner iD

International Journal of Cancer · 15.05.2025 · 156 (10) · 1848-1857

DOI: 10.1002/ijc.35345 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Cancer, online erschienen am 13.02.2025. Verfasst von Matti Lehtinen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vaccines, Institute for Health and Welfare, Helsinki, Finland. Hauptthemen laut MEDLINE: Papillomavirus Vaccines, Papillomavirus Infections. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCI, CCR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Seventeen years after the licensure of prophylactic human papillomavirus (HPV) L1 virus‐like‐particle vaccines, a defined antibody level that correlates with vaccine‐induced protection against HPV infections and associated neoplasia is missing. In contrast, correlates of protection have been defined for many viral vaccines, including for the hepatitis B virus (HBV) vaccine. This review includes lessons learned from vaccination against HBV and the use of an established protective HBV surface antigen antibody level: 10 mIU/mL, an overview of HPV infection‐induced and HPV vaccine‐induced antibody responses, successful efforts to establish international standardization of serological reagents and associated tools, and 15‐year vigilance of HPV vaccine‐induced antibody levels in a vaccination cohort against breakthrough infections. This report identifies progress but also gaps on the journey toward the definition of a HPV vaccine‐induced correlate of protection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus VaccinesPapillomavirus InfectionsHumansFemaleAntibodies, ViralHepatitis B VaccinesVaccination

Stichwörter der Autor:innen

antibodycancerhepatitis B virushuman papillomavirusvaccine

Substanzen

Papillomavirus VaccinesAntibodies, ViralHepatitis B Vaccines

Autor:innen und Institutionen

  • Department of Vaccines, Institute for Health and Welfare, Helsinki, Finland.
  • Center for Cervical Cancer Elimination, Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden.
  • Centre for the Evaluation of Vaccination@Vaccinopolis, Universiteit Antwerp, Antwerp, Belgium.
  • Virus Reference Department, Public Health Microbiology Division, UK Health Security Agency, London, UK.
  • HPV Serology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • Division of Infections and Cancer, Deutsches Krebsforschungszentrum, Heidelberg, Germany.

ORCID-Profile: Matti Lehtinen, Penelope Gray, Joakim Dillner

Förderung

  • NCI NIH HHS
  • NCI
  • CCR NIH HHS
  • HHS
  • National Cancer Institute
  • U.S. Department of Health and Human Services

Zitieren

APA

Lehtinen, M., van Damme, P., Beddows, S., Pinto, L. A., Mariz, F., Gray, P., & Dillner, J. (2025). Scientific approaches to defining HPV vaccine‐induced protective immunity. International Journal of Cancer, 156(10), 1848-1857. https://doi.org/10.1002/ijc.35345

Vancouver

Lehtinen M, van Damme P, Beddows S, Pinto LA, Mariz F, Gray P, et al. Scientific approaches to defining HPV vaccine‐induced protective immunity. International Journal of Cancer. 2025;156(10):1848-1857. doi:10.1002/ijc.35345

BibTeX
@article{Lehtinen2025,
  author = {Lehtinen, Matti and van Damme, Pierre and Beddows, Simon and Pinto, Ligia A and Mariz, Filipe and Gray, Penelope and Dillner, Joakim},
  title = {Scientific approaches to defining HPV vaccine‐induced protective immunity},
  journal = {International Journal of Cancer},
  year = {2025},
  volume = {156},
  number = {10},
  pages = {1848--1857},
  doi = {10.1002/ijc.35345}
}
Kostenlos starten →